

Executive Corridor
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX
Switchboard Tel: 01325 38 0100
Foundation Trust Office: 01325 74 3625
Corporate Records Office: 01325 74 3700

Request for Information Reference: 11.23.15

FOI Direct line: 01325 743700
Email: cdda-tr.cddftfoi@nhs.net

Ms Sarah Webb
Email only

22nd November 2023

Dear Ms Webb

Freedom of Information Act 2000 – Request for Information

Thank you for submitting a request for information which we received on 6th November 2023 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to AML and CLL and I am providing the following information in response to your specific questions:

FOI Request:

The period used for the report is 01/05/2023 to 01/11/2023.

Patients with acute myeloid leukaemia (AML)

1. **How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?**

- | | |
|---|---|
| • Azacitidine monotherapy | 2 |
| • Low dose cytarabine (LoDAC) monotherapy | 0 |
| • Venetoclax + azacitidine | 5 |
| • Venetoclax + LoDAC | 0 |
| • Ivosidenib | 0 |
| • Intensive chemotherapy-based regimen | 0 |
| • Other | 0 |

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?

- Azacitidine monotherapy 0
- Low dose cytarabine (LoDAC) monotherapy 0
- Venetoclax + azacitidine 0
- Venetoclax + LoDAC 0
- Ivosidenib 0
- Intensive chemotherapy-based regimen 0
- Other 0

Note: this should only include patients who have started first-line treatment during the 6-month window

3. Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

5 patients

Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window

- venetoclax monotherapy 23
- venetoclax + rituximab 3
- venetoclax + obinutuzumab 26
- or venetoclax + ibrutinib

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

- venetoclax monotherapy 14
- venetoclax + rituximab 2
- venetoclax + obinutuzumab 16
- or venetoclax + ibrutinib

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via cdda-tr.cddftfoi@nhs.

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; www.ico.gov.uk.

Yours sincerely

Stephen Dawson
Corporate Records and Freedom of Information Facilitator